Expression of the tumor antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in pediatric and adult melanoma: a retrospective case control study.
Cancer vaccine
Pediatric melanoma
Prognostic factor
TAA
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
18 Jun 2024
18 Jun 2024
Historique:
received:
22
04
2024
accepted:
04
06
2024
revised:
17
05
2024
medline:
19
6
2024
pubmed:
19
6
2024
entrez:
18
6
2024
Statut:
aheadofprint
Résumé
Tumor-associated antigens (TAAs) are potential targets for T cell-based immunotherapy approaches in cutaneous melanoma. BNT111, an investigational lipoplex-formulated mRNA-based therapeutic cancer vaccine encoding melanoma TAAs NY-ESO-1, tyrosinase, MAGE-A3, and TPTE, is undergoing clinical testing in adults. Expression of these TAAs in pediatric melanoma is unclear but is a prerequisite for feasibility of this treatment approach in children with melanoma. Our main objective was to characterize expression of those TAAs in pediatric melanomas compared to control cohorts. In this retrospective case control study, protein and transcript expression of NY-ESO-1, tyrosinase, MAGE-A3, and TPTE were analyzed in a cohort of 25 pediatric melanomas, 31 melanomas of young adults, 29 adult melanomas, and 30 benign melanocytic nevi in children using immunohistochemical staining and digital pathology (QuPath) and reverse transcription quantitative PCR. Based on IHC analysis, pediatric melanomas expressed tyrosinase (100.0%), TPTE (44.0%), MAGE-A3 (12.0%), and NY-ESO-1 (8.0%). Young adult melanomas expressed tyrosinase (96.8%), NY-ESO-1 (19.4%), MAGE-A3 (19.4%), and TPTE (3.2%). Adult melanomas expressed tyrosinase (86.2%), MAGE-A3 (75.9%), NY-ESO-1 (48.3%), and TPTE (48.3%). Childhood melanocytic nevi only expressed tyrosinase (93.3%). Expression prevalence of individual TAAs did not differ between subtypes of pediatric melanoma, and no association with prognosis was found. All four TAAs were expressed in pediatric melanoma, albeit NY-ESO-1 and MAGE-A3 to a lesser extent than in adult melanoma. These data support the possibility of investigating vaccines targeting these TAAs for the treatment of pediatric melanoma.
Identifiants
pubmed: 38890171
doi: 10.1007/s00428-024-03846-0
pii: 10.1007/s00428-024-03846-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S (2018) Melanoma Lancet 392(10151):971–984. https://doi.org/10.1016/s0140-6736(18)31559-9
doi: 10.1016/s0140-6736(18)31559-9
pubmed: 30238891
Sacchetto L, Zanetti R, Comber H, Bouchardy C, Brewster D, Broganelli P et al (2018) Trends in incidence of thick, thin and in situ melanoma in Europe. Eur J Cancer 92:108–118. https://doi.org/10.1016/j.ejca.2017.12.024
doi: 10.1016/j.ejca.2017.12.024
pubmed: 29395684
Ferrari A, Brecht IB, Gatta G, Schneider DT, Orbach D, Cecchetto G et al (2019) Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors. Eur J Cancer 110:120–126. https://doi.org/10.1016/j.ejca.2018.12.031
doi: 10.1016/j.ejca.2018.12.031
pubmed: 30785015
Strouse JJ, Fears TR, Tucker MA, Wayne AS (2005) Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol 23(21):4735–4741. https://doi.org/10.1200/jco.2005.02.899
doi: 10.1200/jco.2005.02.899
pubmed: 16034049
Achajew A, Brecht IB, Radespiel-Tröger M, Meyer M, Metzler M, Bremensdorfer C, Spix C, Erdmann F, Schneider DT, Abele M (2022) Rare pediatric tumors in Germany - not as rare as expected: a study based on data from the Bavarian Cancer Registry and the German Childhood Cancer Registry. Eur J Pediatr 181(7):2723–2730. https://doi.org/10.1007/s00431-022-04484-x
doi: 10.1007/s00431-022-04484-x
pubmed: 35478271
pmcid: 9192393
Brecht IB, De Paoli A, Bisogno G, Orbach D, Schneider DT, Leiter U, Offenmueller S, Cecchetto G, Godzinski J, Bien E, Stachowicz-Stencel T, Ben-Ami T, Chiaravalli S, Maurichi A, De Salvo GL, Sorbara S, Bodemer C, Garbe C, Reguerre Y, Ferrari A (2018) Pediatric patients with cutaneous melanoma: a European study. Pediatr Blood Cancer 65(6):e26974. https://doi.org/10.1002/pbc.26974
doi: 10.1002/pbc.26974
pubmed: 29350487
Pampena R, Piccolo V, Muscianese M, Kyrgidis A, Lai M, Russo T, Briatico G, Di Brizzi EV, Cascone G, Pellerone S, Longo C, Moscarella E, Argenziano G (2023) Melanoma in children: a systematic review and individual patient meta-analysis. J Eur Acad Dermatol Venereol 37(9):1758–1776. https://doi.org/10.1111/jdv.19220
doi: 10.1111/jdv.19220
pubmed: 37210654
Merkel EA, Mohan LS, Shi K, Panah E, Zhang B, Gerami P (2019) Paediatric melanoma: clinical update, genetic basis, and advances in diagnosis. The Lancet Child & adolescent health 3(9):646–654. https://doi.org/10.1016/s2352-4642(19)30116-6
doi: 10.1016/s2352-4642(19)30116-6
Ferrari A, Lopez Almaraz R, Reguerre Y, Cesen M, Bergamaschi L, Indini A, Schneider DT, Godzinski J, Bien E, Stachowicz-Stencel T, Eigentler TK, Chiaravalli S, Krawczyk MA, Pappo A, Orbach D, Bisogno G, Brecht IB (2021) Cutaneous melanoma in children and adolescents: the EXPeRT/PARTNER diagnostic and therapeutic recommendations. Pediatr Blood Cancer 68(Suppl 4):e28992. https://doi.org/10.1002/pbc.28992
doi: 10.1002/pbc.28992
pubmed: 34174159
Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC et al (2016) Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534(7607):396–401. https://doi.org/10.1038/nature18300
doi: 10.1038/nature18300
pubmed: 27281205
Simon P, Omokoko TA, Breitkreuz A, Hebich L, Kreiter S, Attig S, Konur A, Britten CM, Paret C, Dhaene K, Türeci Ö, Sahin U (2014) Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes. Cancer Immunol Res 2(12):1230–1244. https://doi.org/10.1158/2326-6066.cir-14-0108
doi: 10.1158/2326-6066.cir-14-0108
pubmed: 25245536
Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15(17):5323–5337. https://doi.org/10.1158/1078-0432.ccr-09-0737
doi: 10.1158/1078-0432.ccr-09-0737
pubmed: 19723653
pmcid: 5779623
Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci 94(5):1914–1918. https://doi.org/10.1073/pnas.94.5.1914
doi: 10.1073/pnas.94.5.1914
pubmed: 9050879
pmcid: 20017
Boyle JL, Haupt HM, Stern JB, Multhaupt HA (2002) Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors: an immunohistochemical study. Arch Pathol Lab Med 126(7):816–822. https://doi.org/10.5858/2002-126-0816-teimmd
doi: 10.5858/2002-126-0816-teimmd
pubmed: 12088451
Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M et al (2020) An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 585(7823):107–112. https://doi.org/10.1038/s41586-020-2537-9
doi: 10.1038/s41586-020-2537-9
pubmed: 32728218
Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD et al (2017) QuPath: open source software for digital pathology image analysis. Sci Rep 7(1):1–7. https://doi.org/10.1038/s41598-017-17204-5
doi: 10.1038/s41598-017-17204-5
Giavina-Bianchi M, Giavina-Bianchi P, Sotto MN, Muzikansky A, Kalil J, Festa-Neto C, Duncan LM (2015) Increased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanoma. J Immunol Res 2015:761378. https://doi.org/10.1155/2015/761378
doi: 10.1155/2015/761378
pubmed: 25954764
pmcid: 4411457
Tio D, Kasiem FR, Willemsen M, van Doorn R, van der Werf N, Hoekzema R, Luiten RM, Bekkenk MW (2019) Expression of cancer/testis antigens in cutaneous melanoma: a systematic review. Melanoma Res 29(4):349–357. https://doi.org/10.1097/cmr.0000000000000569
doi: 10.1097/cmr.0000000000000569
pubmed: 30615012
Al-Batran SE, Rafiyan MR, Atmaca A, Neumann A, Karbach J, Bender A, Weidmann E, Altmannsberger HM, Knuth A, Jäger E (2005) Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Can Res 65(9):3937–3941. https://doi.org/10.1158/0008-5472.can-04-4621
doi: 10.1158/0008-5472.can-04-4621
Brichard V, Van Pel A, Wölfel T, Wölfel C, De Plaen E, Lethé B, Coulie P, Boon T (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178(2):489–495. https://doi.org/10.1084/jem.178.2.489
doi: 10.1084/jem.178.2.489
pubmed: 8340755
Dalerba P, Ricci A, Russo V, Rigatti D, Nicotra MR, Mottolese M, Bordignon C, Natali PG, Traversari C (1998) High homogeneity of MAGE, BAGE, GAGE, Tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: implications for protocol design of therapeutic antigen-specific vaccination strategies. Int J Cancer 77(2):200–204. https://doi.org/10.1002/(sici)1097-0215(19980717)77:2/3C200::aid-ijc5/3E3.0.co;2-u
doi: 10.1002/(sici)1097-0215(19980717)77:2/3C200::aid-ijc5/3E3.0.co;2-u
pubmed: 9650552
Brasseur F, Rimoldi D, Liénard D, Lethé B, Carrel S, Arienti F et al (1995) Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 63(3):375–380. https://doi.org/10.1002/ijc.2910630313
doi: 10.1002/ijc.2910630313
pubmed: 7591235
Lüftl M, Schuler G, Jungbluth A (2004) Melanoma or not? Cancer testis antigens may help. Br J Dermatol 151(6):1213–1218. https://doi.org/10.1111/j.1365-2133.2004.06260.x
doi: 10.1111/j.1365-2133.2004.06260.x
pubmed: 15606517
Jungbluth AA, Iversen K, Coplan K, Kolb D, Stockert E, Chen YT, Old LJ, Busam K (2000) T311—an anti-tyrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues. Pathology-Research and Practice 196(4):235–242. https://doi.org/10.1016/s0344-0338(00)80072-2
doi: 10.1016/s0344-0338(00)80072-2
pubmed: 10782467
Chen H, Rossier C, Morris MA, Scott HS, Gos A, Bairoch A, Antonarakis SE (1999) A testis-specific gene, TPTE, encodes a putative transmembrane tyrosine phosphatase and maps to the pericentromeric region of human chromosomes 21 and 13, and to chromosomes 15, 22, and Y. Hum Genet 105:399–409. https://doi.org/10.1007/s004390051122
doi: 10.1007/s004390051122
pubmed: 10598804
Dong XY, Su YR, Qian XP, Yang XA, Pang XW, Wu HY, Chen WF (2003) Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients. Br J Cancer 89(2):291–297. https://doi.org/10.1038/sj.bjc.6601062
doi: 10.1038/sj.bjc.6601062
pubmed: 12865919
pmcid: 2394243
Singh AP, Bafna S, Chaudhary K, Venkatraman G, Smith L, Eudy JD, Johansson SL, Lin MF, Batra SK (2008) Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. Cancer Lett 259(1):28–38. https://doi.org/10.1016/j.canlet.2007.09.018
doi: 10.1016/j.canlet.2007.09.018
pubmed: 17977648
Chen X, Wang L, Yue D, Liu J, Huang L, Yang L, et al (2017) Correlation between the high expression levels of cancer-germline genes with clinical characteristics in esophageal squamous cell carcinoma. Histol Histopathol. 32(8):793–803. https://doi.org/10.14670/hh-11-847
Ademuyiwa FO, Bshara W, Attwood K, Morrison C, Edge SB, Ambrosone CB et al (2012) NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PLoS ONE 7(6):e38783. https://doi.org/10.1371/journal.pone.0038783
doi: 10.1371/journal.pone.0038783
pubmed: 22761704
pmcid: 3386262
Liebmann A, Admard J, Armeanu-Ebinger S, Wild H, Abele M, Gschwind A, et al. UV-radiation and MC1R germline mutations are risk factors for the development of conventional and spitzoid melanomas in children and adolescents. Ebiomedicine. 96:104797. https://doi.org/10.1016/j.ebiom.2023.104797
Svobodová S, Browning J, MacGregor D, Pollara G, Scolyer RA, Murali R et al (2011) Cancer–testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. Eur J Cancer 47(3):460–469. https://doi.org/10.1016/j.ejca.2010.09.042
doi: 10.1016/j.ejca.2010.09.042
pubmed: 21115342
Freiberger SN, Holzmann D, Morand GB, Hüllner M, Levesque MP, Dummer R, Koelzer VH, Rupp NJ (2022) Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients. J Cancer Res Clin Oncol 149(9):5645–5653. https://doi.org/10.1007/s00432-022-04514-z
doi: 10.1007/s00432-022-04514-z
pubmed: 36527482
pmcid: 10356647